Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**GS24-B057** is a bispecific antibody-drug conjugate (ADC) designed to target both **Nectin-4** and **Trop-2**, two cell surface antigens overexpressed in multiple solid tumors. Developed to enhance clinical efficacy while minimizing toxicity, it features a dual-targeting mechanism with a specified drug-to-antibody ratio (DAR). Preclinical studies position it as a potential best-in-class candidate for treating various solid tumors by delivering cytotoxic payloads selectively to tumor cells expressing these targets.[1][3][5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GS24-B057.